SlideShare une entreprise Scribd logo
1  sur  1
Télécharger pour lire hors ligne
PRESS RELEASE (to be released Tuesday, 29 January 2013)

Cureline Inc. to join the Discovery Summit 2013 at Le Méridien Beach Plaza | Monte-Carlo |
Monaco| 21-22 March 2013

marcus evans is pleased to announce the participation of Cureline Inc. as a Sponsor at the Discovery
Summit 2013 taking place at Le Méridien Beach Plaza | Monte-Carlo | Monaco 21-22 March 2013.

The Discovery Summit provides a unique and exclusive forum for global R&D professionals and drug
discovery sponsors to focus in an intimate environment on discussions around key new drivers
shaping discovery research and development today. More details about the Discovery Summit 2013
can be found here.

Cureline is a global biomarker and diagnostics CRO specialising since 2003 in human biospecimen
acquisition and tissue research projects including study design, regulatory affairs, clinical network
management, specimen collection and analysis, and complete logistics. Our major areas of expertise
are oncology, inflammation/autoimmune diseases, cardiovascular conditions, metabolic conditions,
infectious diseases/sepsis/HIV, maternal/fetal health, and IVD testing. We collaborate with major
clinical and research centres in Europe, Asia, Central and South America and the USA, and maintain
an extensive biorepository of human biospecimens in South San Francisco (USA). Cureline
BioPathology (translational histology CLIA/GLP laboratory) provides high-end tissue research services
including IHC protocol development, clinical specimens processing and diagnostics, and digital
pathology. Clinical outreach group in St. Petersburg (Russia) supports regulatory affairs, patient
enrolment and retention services, clinical site relation management, and marketing research. All our
managers have advanced degrees in medicine/life sciences and are experienced in clinical trial
operations, research and healthcare management and international business development.
www.cureline.com

For further information on the Discovery Summit 2013 programme please contact
Ruth Abbott
Marketing PR & Communications Director
ruth.PRsummits@marcusevans.com
marcus evans

Contenu connexe

Plus de Life Sciences Network marcus evans

How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKHow Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKLife Sciences Network marcus evans
 
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Life Sciences Network marcus evans
 
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Life Sciences Network marcus evans
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedLife Sciences Network marcus evans
 
Turning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessTurning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessLife Sciences Network marcus evans
 
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Life Sciences Network marcus evans
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Life Sciences Network marcus evans
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...Life Sciences Network marcus evans
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Life Sciences Network marcus evans
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Life Sciences Network marcus evans
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Life Sciences Network marcus evans
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Life Sciences Network marcus evans
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Life Sciences Network marcus evans
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Life Sciences Network marcus evans
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Life Sciences Network marcus evans
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Life Sciences Network marcus evans
 
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic RhinoconjunctivitisCRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic RhinoconjunctivitisLife Sciences Network marcus evans
 

Plus de Life Sciences Network marcus evans (20)

How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKHow Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
 
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
 
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
 
Turning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessTurning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for Success
 
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
 
Business Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENABusiness Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENA
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
 
Where marcus evans fits in our business development mix
Where marcus evans fits in our business development mixWhere marcus evans fits in our business development mix
Where marcus evans fits in our business development mix
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
 
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic RhinoconjunctivitisCRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
 
Grow Your Business
Grow Your BusinessGrow Your Business
Grow Your Business
 

Cureline Inc. to join the Discovery Summit 2013 at Le Méridien Beach Plaza, Monte-Carlo, Monaco, 21-22 March 2013

  • 1. PRESS RELEASE (to be released Tuesday, 29 January 2013) Cureline Inc. to join the Discovery Summit 2013 at Le Méridien Beach Plaza | Monte-Carlo | Monaco| 21-22 March 2013 marcus evans is pleased to announce the participation of Cureline Inc. as a Sponsor at the Discovery Summit 2013 taking place at Le Méridien Beach Plaza | Monte-Carlo | Monaco 21-22 March 2013. The Discovery Summit provides a unique and exclusive forum for global R&D professionals and drug discovery sponsors to focus in an intimate environment on discussions around key new drivers shaping discovery research and development today. More details about the Discovery Summit 2013 can be found here. Cureline is a global biomarker and diagnostics CRO specialising since 2003 in human biospecimen acquisition and tissue research projects including study design, regulatory affairs, clinical network management, specimen collection and analysis, and complete logistics. Our major areas of expertise are oncology, inflammation/autoimmune diseases, cardiovascular conditions, metabolic conditions, infectious diseases/sepsis/HIV, maternal/fetal health, and IVD testing. We collaborate with major clinical and research centres in Europe, Asia, Central and South America and the USA, and maintain an extensive biorepository of human biospecimens in South San Francisco (USA). Cureline BioPathology (translational histology CLIA/GLP laboratory) provides high-end tissue research services including IHC protocol development, clinical specimens processing and diagnostics, and digital pathology. Clinical outreach group in St. Petersburg (Russia) supports regulatory affairs, patient enrolment and retention services, clinical site relation management, and marketing research. All our managers have advanced degrees in medicine/life sciences and are experienced in clinical trial operations, research and healthcare management and international business development. www.cureline.com For further information on the Discovery Summit 2013 programme please contact Ruth Abbott Marketing PR & Communications Director ruth.PRsummits@marcusevans.com marcus evans